



CS/NSE/UFR/2014-15
February 10, 2015

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

To
The General Manager
Department of Corporate Services
Bombay Stock Exchange Ltd
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

Stock Code: SUVEN - EQ

Stock Code: 530239

Dear Sir/Madam,

Sub: Notification of Un-audited Financial Results for the quarter /nine months ended December 31, 2014 – Clause 41


.....

With reference to the above subject, we are forwarding herewith **Un-audited Financial Results of our Company for quarter /nine months ended 31st December, 2014** in the prescribed proforma, as required under Clause-41 of the listing agreement as amended. The Board of Directors of our company has taken on record the enclosed Un-audited Financial Results for the third quarter in its meeting held on 10th February, 2015 and **Limited Review Report of Auditors of the Company**.

Mr. P. Subba Rao, the GM (Finance & Costing) has been appointed as Chief Financial Officer (CFO) of the Company by the Board.

Please find enclosed Press release of our company. We request you to take these documents on your records.

Thanking you,
Yours faithfully,
For **Suven Life Sciences Limited**


K Hanumantha Rao
Company Secretary

Suven Life Sciences Limited

CIN: L24110TG1989PLC009713

Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor I

Road No.5 I Avenue 7 I Banjara Hills I Hyderabad – 500 034 I Telangana I India

Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com



SUVEN LIFE SCIENCES LTD

Regd. Off: 8-2-334, SDE Serene Chambers, 6th Floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500 034 CIN: L24110TG1989PLC009713

Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: investorservices@suvlen.com website: www.suvlen.com

STATEMENT OF UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2014

PART - I

Rs. in lakhs

Sl. No.	PARTICULARS	Quarter ended			Nine months ended		Previous year ended
		31/12/2014	30/09/2014	31/12/2013	31/12/2014	31/12/2013	31/03/2014
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
1	Income from operations						
	(a) Net sales/income from operations (Net of excise duty)	12,882.97	13,983.12	11,942.71	41,019.25	37,950.90	51,031.24
	(b) Other operating income	-	-	-	-	-	-
	Total income from operations (net) (a)+(b)	12,882.97	13,983.12	11,942.71	41,019.25	37,950.90	51,031.24
2	Expenses						
	a) Cost of materials consumed	4,413.80	4,068.03	3,576.20	13,177.17	11,151.23	15,049.65
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,020.96)	2,078.07	(1,024.28)	1,009.23	(1,737.23)	(1,397.66)
	d) Employee benefits expense	963.42	781.19	893.97	2,655.98	2,433.59	3,144.21
	e) Depreciation and amortisation expense	244.73	248.08	224.83	731.67	656.23	883.74
	f) Other expenses - Manufacturing Expenses	1,812.03	1,552.85	1,340.82	4,804.49	3,788.65	5,388.94
	- R & D Expenses	1,279.47	1,098.72	973.08	3,273.08	3,556.74	4,794.79
	- Others	602.51	565.29	694.40	1,639.47	1,824.99	2,145.45
	Total expenses	8,295.00	10,392.23	6,679.02	27,291.09	21,674.20	30,009.12
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	4,587.97	3,590.89	5,263.69	13,728.16	16,276.70	21,022.12
4	Other Income	227.13	141.98	84.96	477.05	411.90	302.95
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4)	4,815.10	3,732.87	5,348.65	14,205.21	16,688.60	21,325.07
6	Finance costs	100.55	132.99	221.43	349.96	881.77	1,051.28
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	4,714.55	3,599.88	5,127.22	13,855.25	15,806.83	20,273.79
8	Exceptional Items (Ref: Note No.4 below)	236.58	322.06	-	964.63	-	-
9	Profit/Loss from Ordinary Activities before tax (7+8)	4,477.97	3,277.82	5,127.22	12,890.62	15,806.83	20,273.79
10	Tax Expenses	1,255.31	794.17	1,483.90	3,710.49	4,631.64	5,858.04
11	Net Profit/ (Loss) from Ordinary Activities after tax (9-10)	3,222.66	2,483.65	3,643.32	9,180.13	11,175.19	14,415.75
12	Extraordinary Items (net of tax expense Rs.____)	-	-	-	-	-	-
13	Net Profit / (Loss) for the period (11 + 12)	3,222.66	2,483.65	3,643.32	9,180.13	11,175.19	14,415.75
14	Share of profit / (loss) of associates	-	-	-	-	-	-
15	Minority interest	-	-	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)	3,222.66	2,483.65	3,643.32	9,180.13	11,175.19	14,415.75
17	Paid-up equity share capital (Face Value of Rs. 1/- each)	1,272.82	1,168.29	1,168.29	1,272.82	1,168.29	1,168.29
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	25,276.34
19.i	Earnings Per Share (EPS) (before extraordinary items) (of Rs.1/- each) (not annualised):						
	a) Basic	2.73	2.13	3.12	7.78	9.57	12.34
	b) Diluted	2.73	2.13	3.12	7.78	9.57	12.34
19.ii	Earnings Per Share (EPS) (after extraordinary items) (of Rs.1/- each) (not annualised):						
	a) Basic	2.73	2.13	3.12	7.78	9.57	12.34
	b) Diluted	2.73	2.13	3.12	7.78	9.57	12.34


PART - II							
A	PARTICULARS OF SHAREHOLDING	31/12/2014	30/09/2014	31/12/2013	31/12/2014	31/12/2013	31/03/2014
1	Public share holdings						
	a. Number of shares	51,624,902	41,171,212	41,171,212	51,624,902	41,171,212	41,171,212
	b. Percentage of share holding	40.56%	35.24%	35.24%	40.56%	35.24%	35.24%
2	Promoters and promoter group Shareholding						
	a) Pledged / Encumbered						
	- Number of shares	NIL	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total share capital of the company)	NIL	NIL	NIL	NIL	NIL	NIL
	b) Non-Encumbered						
	- Number of shares	75,657,576	75,657,576	75,657,576	75,657,576	75,657,576	75,657,576
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the company)	59.44%	64.76%	64.76%	59.44%	64.76%	64.76%
Particulars		3 months ended (31/12/2014)					
B	INVESTOR COMPLAINTS						
	Pending at the beginning of the quarter	-					
	Received during the quarter	37					
	Disposed of during the quarter	37					
	Remaining unresolved at the end of the quarter	-					

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED							
	PARTICULARS	Quarter ended			Nine months ended		Previous year ended
		31/12/2014	30/09/2014	31/12/2013	31/12/2014	31/12/2013	31/03/2014
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
1	SEGMENT REVENUE						
	a) Manufacturing (CRAMS)	12,328.69	13,006.64	11,229.62	39,230.28	36,660.43	49,344.00
	b) Services (DDDSS)	554.28	976.48	713.08	1,788.97	1,290.46	1,687.24
	c) Research & Development	-	-	-	-	-	-
	Net sales/income from operations	12,882.97	13,983.12	11,942.70	41,019.25	37,950.89	51,031.24
2	SEGMENT RESULTS (Profit/(Loss) before tax and interest)						
	a) Manufacturing (CRAMS)	6,137.28	4,300.75	6,327.79	17,169.08	20,367.42	26,308.56
	b) Services (DDDSS)	174.33	737.95	459.14	947.17	687.99	888.72
	c) Research & Development	(1,469.96)	(1,347.49)	(973.08)	(4,058.80)	(3,556.74)	(4,794.79)
	TOTAL	4,841.65	3,691.21	5,813.85	14,057.45	17,498.67	22,402.49
	Less: (i) Interest	65.34	81.87	117.92	224.77	529.48	618.92
	(ii) Other Un-allocable expenses net off	298.34	331.52	568.71	942.06	1,162.36	1,509.78
	(iii) un-allocable Income	-	-	-	-	-	-
	Profit Before Tax	4,477.97	3,277.82	5,127.22	12,890.62	15,806.83	20,273.79
3	CAPITAL EMPLOYED (Segment Assets-Segment Liabilities)						
	a) Manufacturing (CRAMS)	30,723.12	24,305.89	20,220.18	30,723.12	20,220.18	17,807.16
	b) Services (DDDSS)	3,170.05	3,211.14	3,387.00	3,170.05	3,387.00	3,434.62
	c) Research & Development	841.37	1,377.68	1,799.48	841.37	1,799.48	1,460.97
	d) Un-allocated	29,106.35	9,912.25	8,292.38	29,106.35	8,292.38	10,453.81
	TOTAL	63,840.89	38,806.96	33,699.04	63,840.89	33,699.04	33,156.56

Notes:

- 1) The above Un-audited results were approved and taken on record at the Board of Directors' Meeting held on 10th February, 2015.
- 2) Previous year(s) figures have been regrouped/reclassified whenever necessary.
- 3) The above results are reviewed by the Statutory Auditors.
- 4) The depreciation has been computed as per Schedule II of the Companies Act 2013 effective April 1, 2014. Accordingly the depreciation which is higher is shown as exceptional item under Sl. No. 8 above. Further, based on transitional provision in note 7(b) of schedule II an amount of **Rs. 473.50 lakhs** (net of deferred tax of **Rs. 243.81 lakhs**) has been adjusted with the opening Reserves.
- 5) The company has raised Rs. 200.00 Crores through QIP issue by allotment of 1,04,53,690 Equity shares of face value Re.1.00 each at a premium of Rs. 190.32 per share on 3rd December 2014.
- 6) Un-allocated assets as at 31st Dec '2014 includes total investments of Rs.23330.15 lakhs.

For SUVEN LIFE SCIENCES LTD



Place : Hyderabad
Date: 10th February, 2015

VENKAT JASTI
Chairman & CEO

We Deliver



Ref No.LR/009/2014-15:

LIMITED REVIEW REPORT

To

The Board of Directors of
M/s. SUVEN LIFE SCIENCES LIMITED

We have reviewed the accompanying statement of unaudited financial results of M/S. SUVEN LIFE SCIENCES LIMITED, having registered office at 8-2-334, 6th Floor, SDE Serene Chambers, Road No.7, Banjara Hills, Hyderabad – 34, for the period ended on 31.12.2014, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India*. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

for KARVY & CO.,
Chartered Accountants
(Registration No.001757S)


(K. AJAY KUMAR)
P A R T N E R
M.No.021989



Place: Hyderabad
Date : 10/02/2015



News Release

Suven Revenue growth at 9% while PAT is down by 11.55% for the 3rd Quarter ended Dec 2014

HYDERABAD, INDIA (February 10, 2015) – SUVEN Life Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its Un-audited Financial Results for the quarter ended 31st Dec 2014. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on Feb 10th 2015 at Hyderabad.

Financial Highlights for the 3rd Quarter ended Dec' 2014:

Growth in revenue	Rs 1311 Mn vs Rs 1203 Mn	- up by 9 %
Growth in PAT	Rs 322 Mn vs. Rs 364 Mn	- down by 11.55%
Growth in EBITDA	Rs 506 Mn vs. Rs 557 Mn	- down by 9.22%

Financial Highlights for the 9 Months ended Dec' 2014:

Growth in revenue	Rs 4150 Mn vs Rs 384 Mn	- up by 8.17%
Growth in PAT	Rs 918 Mn vs. Rs 1117 Mn	- down by 17.85%
Growth in EBITDA	Rs 1494 Mn vs. Rs 1734 Mn	- down by 13.88%

PAT for the current quarter was reduced by Rs. 23.66 Mn & for the 3rd Qtr ended 31st Dec'2014 reduced by Rs.96.46 Mn due to charge of additional depreciation computed as per Schedule II of the Companies Act 2013 effective April 1, 2014, shown as exceptional item in Profit & Loss Account. If the similar provisions of same quarter of previous years followed the PAT for this quarter would have been higher by Rs. 23.66 Mn to Rs 345.9 million and PAT for the 3rd Qtr ended 31st Dec'2014 would have been higher by Rs.96.46 million to Rs 1014.47 million

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 406 Mn (9.78% on revenue) for the 3rd Qtr ended 31st Dec'2014

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;

Suven Life Sciences Limited

CIN: L24110TG1989PLC009713

Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor I

Road No.5 I Avenue 7 I Banjara Hills I Hyderabad – 500 034 I Telangana I India

Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com